BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33361876)

  • 1. Delayed Methotrexate Elimination after Administration of a Medium Dose of Methotrexate in a Patient with Genetic Variants Associated with Methotrexate Clearance.
    Tatebe Y; Kanamitsu K; Kanzaki H; Ishida H; Fujiwara K; Washio K; Kitamura Y; Sendo T; Shimada A; Tsukahara H
    Acta Med Okayama; 2020 Dec; 74(6):545-550. PubMed ID: 33361876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.
    Treviño LR; Shimasaki N; Yang W; Panetta JC; Cheng C; Pei D; Chan D; Sparreboom A; Giacomini KM; Pui CH; Evans WE; Relling MV
    J Clin Oncol; 2009 Dec; 27(35):5972-8. PubMed ID: 19901119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition.
    Ramsey LB; Bruun GH; Yang W; Treviño LR; Vattathil S; Scheet P; Cheng C; Rosner GL; Giacomini KM; Fan Y; Sparreboom A; Mikkelsen TS; Corydon TJ; Pui CH; Evans WE; Relling MV
    Genome Res; 2012 Jan; 22(1):1-8. PubMed ID: 22147369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.
    Radtke S; Zolk O; Renner B; Paulides M; Zimmermann M; Möricke A; Stanulla M; Schrappe M; Langer T
    Blood; 2013 Jun; 121(26):5145-53. PubMed ID: 23652803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia.
    Cheng Y; Chen MH; Zhuang Q; Lin BJ; Chen YY; Yang L; Liu MB; Que WC; Qiu HQ
    Pediatr Blood Cancer; 2021 May; 68(5):e28858. PubMed ID: 33501733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations.
    Rau T; Erney B; Göres R; Eschenhagen T; Beck J; Langer T
    Clin Pharmacol Ther; 2006 Nov; 80(5):468-76. PubMed ID: 17112803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between a microRNA binding site polymorphism in SLCO1A2 and the risk of delayed methotrexate elimination in Chinese children with acute lymphoblastic leukemia.
    Wang SM; Zeng WX; Wu WS; Sun LL; Yan D
    Leuk Res; 2018 Feb; 65():61-66. PubMed ID: 29306656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
    Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
    Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma.
    Shimasaki N; Mori T; Samejima H; Sato R; Shimada H; Yahagi N; Torii C; Yoshihara H; Tanigawara Y; Takahashi T; Kosaki K
    J Pediatr Hematol Oncol; 2006 Feb; 28(2):64-8. PubMed ID: 16462575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Assessment of elimination and tolerance of high dose of methotrexate (3 g/m2) in children with standard-risk acute lymphoblastic leukemia].
    Cwliklińska M; Balwierz W; Nowak J; Stanuch H
    Przegl Lek; 2006; 63(1):15-20. PubMed ID: 16892893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of SLCO1B1 Polymorphisms on High-Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma.
    Schulte RR; Choi L; Utreja N; Van Driest SL; Stein CM; Ho RH
    Clin Transl Sci; 2021 Jan; 14(1):343-353. PubMed ID: 32961024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between MTHFR microRNA binding site polymorphisms and methotrexate concentrations in Chinese pediatric patients with acute lymphoblastic leukemia.
    Wang SM; Zeng WX; Wu WS; Sun LL; Yan D
    J Gene Med; 2017 Nov; 19(11):353-359. PubMed ID: 28990296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of
    Yang FF; Xue TL; Gao C; Wu Y; Lin W; Li J; Zhang RD; Zheng HY; Liu SG
    Pharmacogenomics; 2022 Oct; 23(15):821-834. PubMed ID: 36193736
    [No Abstract]   [Full Text] [Related]  

  • 14. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.
    Lopez-Lopez E; Martin-Guerrero I; Ballesteros J; Piñan MA; Garcia-Miguel P; Navajas A; Garcia-Orad A
    Pediatr Blood Cancer; 2011 Oct; 57(4):612-9. PubMed ID: 21387541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide study of methotrexate clearance replicates SLCO1B1.
    Ramsey LB; Panetta JC; Smith C; Yang W; Fan Y; Winick NJ; Martin PL; Cheng C; Devidas M; Pui CH; Evans WE; Hunger SP; Loh M; Relling MV
    Blood; 2013 Feb; 121(6):898-904. PubMed ID: 23233662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of plasma methotrexate level and MTHFR genotype in Korean paediatric patients with acute lymphoblastic leukaemia.
    Chae H; Kim M; Choi SH; Kim SK; Lee JW; Chung NG; Cho B; Kim Y
    J Chemother; 2020 Sep; 32(5):251-259. PubMed ID: 32431230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate.
    Zhang HN; He XL; Wang C; Wang Y; Chen YJ; Li JX; Niu CH; Gao P
    Pediatr Blood Cancer; 2014 Dec; 61(12):2203-7. PubMed ID: 25130190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma.
    Kantar M; Kosova B; Cetingul N; Gumus S; Toroslu E; Zafer N; Topcuoglu N; Aksoylar S; Cinar M; Tetik A; Eroglu Z
    Leuk Lymphoma; 2009 Jun; 50(6):912-7. PubMed ID: 19391036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia.
    Lopez-Lopez E; Ballesteros J; Piñan MA; Sanchez de Toledo J; Garcia de Andoin N; Garcia-Miguel P; Navajas A; Garcia-Orad A
    Pharmacogenet Genomics; 2013 Feb; 23(2):53-61. PubMed ID: 23222202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
    Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P
    Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.